RxDoctor Payments Data

Harjit Gogna, MD

Internal Medicine · Modesto, CANPI 1558411322

Payments from drug & device makers

$540in general payments, 2019–2025

Across 28 payments — averaging $19.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$91
  • AstraZeneca$76
  • Novo Nordisk$76
  • Galderma Laboratories, L.p.$70
  • GSK$38
  • Exact Sciences$33
  • plus $157 from 8 others

What the payments were for

  • Food & beverage$540100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$540 in reported general payments places this provider in the 65th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$30,121
Medicare patients
111
Services billed
295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$121,427
JardianceEmpagliflozin104$103,689
TrulicityDulaglutide66$79,531
JanuviaSitagliptin Phosphate62$62,074
FarxigaDapagliflozin Propanediol39$49,784
EliquisApixaban25$26,369
TradjentaLinagliptin34$21,968
EntrestoSacubitril/Valsartan21$15,754
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$7,780
Breo ElliptaFluticasone/Vilanterol17$7,187
Albuterol Sulfate HfaAlbuterol Sulfate167$6,261
Atorvastatin Calcium660$5,553
Lantus SolostarInsulin Glargine,hum.Rec.Anlog57$4,894
Wixela InhubFluticasone Propion/Salmeterol29$3,752
Advair HfaFluticasone Propion/Salmeterol12$3,713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$76$121,427118 claims
AstraZenecaFarxiga$76$49,78439 claims
NovartisEntresto$17$15,75421 claims
GSKBreo Ellipta$38$7,18717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →